EGFR and head and neck squamous cell carcinoma: Likewise, an oncolytic adenovirus (Onc.Ad) expressing an EGFR-BiTE (Onc.Ad-EGFR.BiTE), derived from cetuximab which is used clinically to treat colorectal (28) and head-and-neck squamous cell carcinomas (29), was able to induce ex vivo activated, adoptively transferred T-cell accumulation and proliferation in a subcutaneous model of colorectal carcinoma.